List of Excipients in Branded Drug MULPLETA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SHIONOGI INC	MULPLETA	lusutrombopag	59630-551	CARBOXYMETHYLCELLULOSE CALCIUM	2030-01-21
SHIONOGI INC	MULPLETA	lusutrombopag	59630-551	CELLULOSE, MICROCRYSTALLINE	2030-01-21
SHIONOGI INC	MULPLETA	lusutrombopag	59630-551	FERRIC OXIDE RED	2030-01-21
SHIONOGI INC	MULPLETA	lusutrombopag	59630-551	HYDROXYPROPYL CELLULOSE	2030-01-21
SHIONOGI INC	MULPLETA	lusutrombopag	59630-551	HYPROMELLOSE	2030-01-21

MULPLETA Excipient Strategy and Commercial Opportunities for Lusutrombopag

Last updated: August 22, 2026

MULPLETA contains 3 mg of lusutrombopag in an immediate-release film-coated tablet. Its excipient platform is conventional, low-cost and suitable for generic development, but the product creates commercial opportunities in content uniformity, tablet robustness, coating appearance, supply security and lifecycle reformulation. The main strategic risk is not excipient scarcity. It is demonstrating equivalent drug release and exposure from a low-dose tablet used in patients with chronic liver disease who require a scheduled invasive procedure.

What is MULPLETA and which excipients does it contain?

MULPLETA is the U.S. brand name for lusutrombopag, an oral thrombopoietin receptor agonist approved by the FDA in 2018. It is indicated for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.[1]

The dosage form is a 3 mg yellow, round, film-coated tablet. The U.S. prescribing information identifies the following inactive ingredients:[1]

Formulation component	Function	Commercial relevance
Mannitol	Diluent, bulking agent, mouthfeel modifier	Important for tablet mass and compression behavior
Microcrystalline cellulose	Diluent and dry binder	Supports direct compression and mechanical strength
Croscarmellose sodium	Superdisintegrant	Controls tablet breakup and may influence dissolution
Magnesium stearate	Lubricant	Requires controlled mixing to avoid dissolution or tensile-strength effects
Hypromellose	Film former	Supports coating adhesion and protection
Titanium dioxide	Opacifier and pigment	Affects color consistency and coating opacity
Talc	Anti-tacking and coating aid	Supports film-coating process control
Ferric oxide-based colorant	Colorant	Supports product identification and brand appearance

The excipient profile does not depend on a novel delivery system, lipid vehicle, modified-release matrix or complex biologic stabilizer. That reduces manufacturing complexity and creates a relatively accessible platform for generic and contract-manufacturing development.

What excipient strategy is most appropriate for a generic MULPLETA tablet?

A generic formulation should initially mirror the reference product’s qualitative excipient architecture while optimizing quantitative composition through design-of-experiments work. The lowest-risk strategy is a conventional immediate-release tablet using mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

Direct compression versus granulation

Direct compression is commercially attractive because it reduces processing steps, solvent use, equipment requirements and batch-cycle time. Microcrystalline cellulose and spray-dried or granular mannitol can provide adequate flow and compactability.

Wet granulation may become necessary if the active pharmaceutical ingredient has poor flow, low bulk density, segregation risk or inadequate tablet tensile strength. A granulation route can improve content uniformity, but it increases process validation burden and may create additional stability questions.

A practical development sequence is:

1. Screen direct-compression grades of mannitol and microcrystalline cellulose.
2. Measure powder flow, segregation, ejection force and compactibility.
3. Optimize croscarmellose sodium location, either intragranular, extragranular or split.
4. Establish a narrow magnesium stearate blending window.
5. Compare dissolution against the reference product across multiple pH conditions.

Low-dose content uniformity

Lusutrombopag represents a small fraction of total tablet weight. That makes blend homogeneity and segregation control central formulation risks. The excipient system should support:

• Similar particle-size distribution between active ingredient and major diluents.
• Low-density segregation control during transfer and hopper discharge.
• Sufficient blend sampling and process monitoring.
• Defined lubrication time limits.
• Tablet weight and assay controls capable of detecting localized API variation.

A formulation that uses a high-load mannitol system may improve manufacturability and patient acceptability but can increase segregation if the API and excipient particle sizes differ materially.

What commercial opportunities exist for excipient suppliers?

The strongest opportunities are in differentiated grades and technical services rather than in commodity excipient supply.

1. Co-processed mannitol-cellulose systems

A co-processed mannitol and microcrystalline cellulose platform could provide better flow, compactability and content-uniformity performance than separate excipient additions. Suppliers could position such systems for:

• Direct compression of low-dose APIs.
• Reduced tablet-weight variability.
• Lower friability at moderate compression force.
• Faster scale-up from laboratory to commercial press.
• Reduced dependence on wet granulation.

The commercial value increases if the co-processed excipient reduces manufacturing steps without changing the finished-product dissolution profile.

2. Premium croscarmellose sodium grades

Croscarmellose sodium is a commodity superdisintegrant, but particle-size distribution, swelling behavior and wicking performance vary by grade. Suppliers can differentiate through:

• Faster disintegration at low use levels.
• More consistent performance under high compression force.
• Better compatibility with mannitol-based tablets.
• Lower batch-to-batch variability.
• Technical support for dissolution matching.

The supplier must avoid claiming therapeutic differentiation. The commercial argument is manufacturing consistency and regulatory support.

3. Magnesium stearate alternatives

Magnesium stearate is inexpensive and widely available, but over-lubrication can reduce tablet hardness and slow wetting or dissolution. Opportunities include:

• Lower-surface-area magnesium stearate grades.
• Controlled particle-size products.
• Alternative vegetable-derived stearates.
• Lubricant blends designed for shorter mixing times.
• Technical packages supporting reduced lubrication sensitivity.

A lubricant change should be treated as a critical formulation variable because the drug product is an immediate-release tablet.

4. Ready-to-use film-coating systems

The yellow film coat creates an opportunity for premixed coating suppliers. A ready-to-use system can reduce color matching, simplify batch records and improve visual consistency. The principal requirements are:

• Color equivalence to the reference product.
• Consistent coating weight gain.
• Low risk of logo or imprint obscuration.
• Adequate moisture protection.
• Compatibility with tablet core porosity and surface texture.

Titanium dioxide regulatory requirements differ by jurisdiction. A supplier offering titanium-dioxide-free alternatives may access markets where restrictions apply, but the replacement must preserve opacity and color performance.

5. Supply-chain and dual-sourcing programs

MULPLETA’s excipients are widely available, but pharmaceutical companies still face qualification costs, regional shortages and supplier concentration. Excipient suppliers can create value through:

• Dual-site manufacturing.
• Compendial and non-compendial grade mapping.
• Regulatory change-notification systems.
• Regional inventory hubs.
• Low-volume commercial supply for orphan or specialty products.
• Documentation packages for ANDA and post-approval change submissions.

The opportunity is strongest for suppliers that combine material supply with formulation troubleshooting and regulatory documentation.

What formulation patents protect MULPLETA?

The public prescribing information identifies the formulation composition but does not establish the full patent estate. Excipients listed in the label are not, by themselves, evidence of patent protection. A company evaluating a generic or reformulated product must separate:

• Active-ingredient composition patents.
• Solid-form or crystalline-state patents.
• Tablet formulation patents.
• Manufacturing-process patents.
• Method-of-use patents.
• Regulatory exclusivity.

For commercial planning, excipient substitution can reduce formulation overlap, but it does not eliminate infringement risk if claims cover the active ingredient, dosage regimen, solid form or broad pharmaceutical composition.

What is the Orange Book status of MULPLETA?

MULPLETA is an FDA-approved NDA drug product. FDA approval does not mean that every commercial barrier is formulation-based. The relevant questions are whether the Orange Book contains active patent listings, whether regulatory exclusivity has expired, and whether any listed claims cover the proposed generic product or its use.[2]

Lusutrombopag received approval as a new molecular entity in 2018. The five-year NCE exclusivity period would have run from approval in 2018 into 2023, subject to the precise FDA exclusivity calculation.[3] Patent terms may extend beyond regulatory exclusivity.

When does MULPLETA lose exclusivity and what does that mean for excipient suppliers?

Regulatory exclusivity and patent expiry are separate events. The end of NCE exclusivity permits certain generic filing activity, but commercial launch still depends on patent status, litigation, approval timing and manufacturing readiness.

For excipient suppliers, the commercial window often opens before generic launch. Formulation developers must qualify materials during:

• Reference-product reverse engineering.
• Pre-formulation studies.
• Pilot-scale tablet manufacture.
• Bioequivalence batches.
• ANDA stability production.
• Commercial process validation.

Suppliers that enter at the reverse-engineering stage have a stronger chance of retaining business through approval because changing excipients late in development can trigger comparability, stability or bioequivalence work.

How strong is the MULPLETA patent estate from an excipient perspective?

From an excipient perspective, the product appears less difficult than drugs protected by complex delivery technology. The tablet uses standard excipients and an immediate-release format. That limits the technical barrier to formulation replication.

The main development barriers are:

• Low-dose API distribution.
• Dissolution matching.
• Tablet mechanical properties.
• Film-coat color matching.
• Control of lubricant impact.
• Demonstration of bioequivalence.
• Freedom-to-operate analysis for active-ingredient and method-of-use claims.

An excipient strategy that produces a materially different release profile could create avoidable regulatory work. The preferred approach is sameness where practical, followed by targeted substitution where the alternative improves supply security, manufacturability or jurisdictional compliance.

What FDA regulatory issues affect excipient changes?

For an ANDA, excipient changes can affect pharmaceutical equivalence, bioequivalence, stability and product quality. FDA scrutiny is likely to focus on whether the proposed product has the same dosage form, strength, route of administration and active ingredient, and whether differences in inactive ingredients affect performance.[4]

Key controls include:

Development area	Relevant control
Blend uniformity	Sampling plan, segregation studies, assay mapping
Tablet hardness	Compression-force range and dissolution impact
Disintegration	Time limits linked to dissolution performance
Lubrication	Mixing-time and lubricant-level studies
Film coating	Weight gain, color, defects and moisture exposure
Stability	Long-term and accelerated studies in commercial packaging
Bioequivalence	Comparative exposure and, where applicable, comparative dissolution
Supplier changes	Change-control and regulatory-impact assessment

A reformulator should avoid unnecessary excipient innovation unless it solves a defined problem. In a small specialty product, the cost of additional regulatory and clinical development can exceed the savings from a cheaper ingredient.

What generic launch scenarios exist for MULPLETA?

Three launch strategies are commercially plausible.

Scenario 1: Reference-matched generic

This approach uses the same or closely comparable excipient classes and targets the fastest development path. It is suitable for companies prioritizing approval speed and lower formulation risk.

Scenario 2: Cost-optimized generic

The manufacturer replaces premium grades with lower-cost compendial materials and optimizes the process around direct compression. This can improve gross margin but increases the risk of dissolution or content-uniformity differences.

Scenario 3: Supply-resilient generic

The company qualifies multiple suppliers for mannitol, microcrystalline cellulose, croscarmellose sodium and coating materials. The product may not have the lowest unit cost, but it can reduce interruption risk and support multi-region launches.

The third strategy is commercially relevant for specialty medicines with lower volumes, where a single excipient disruption can stop finished-product production.

How does MULPLETA compare with competing thrombocytopenia products?

MULPLETA competes mainly with avatrombopag, marketed as DOPTELET, for periprocedural thrombocytopenia associated with chronic liver disease. Both are oral thrombopoietin receptor agonists, but their formulation and commercial strategies differ.[5]

Attribute	MULPLETA	DOPTELET
Active ingredient	Lusutrombopag	Avatrombopag
Dosage form	Immediate-release tablet	Immediate-release tablet
Core commercial use	Increase platelet count before scheduled procedures	Increase platelet count before scheduled procedures
Excipient opportunity	Low-dose uniformity, direct compression, coating and supply resilience	Similar tablet-manufacturing opportunities
Competitive factor	Procedure scheduling, dosing convenience, physician familiarity and access	Same
Biosimilar risk	Not applicable as a small-molecule drug	Not applicable as a small-molecule drug

Biosimilar development is not relevant to MULPLETA because lusutrombopag is a small-molecule active ingredient, not a biologic. The competitive risk comes from generic entry, DOPTELET substitution and payer contracting.

What licensing deals and manufacturing barriers affect the opportunity?

Lusutrombopag was developed by Shionogi. Commercial assessments should distinguish between licensing rights for the active ingredient and excipient procurement. An excipient supplier generally does not need a license to supply standard compendial materials, but it may need confidentiality agreements, quality agreements and technical-transfer support with the finished-dose manufacturer.

Manufacturing barriers are moderate:

• No cold chain is required for the tablet product.
• The dosage form uses standard solid-dose equipment.
• Excipient availability is broad.
• Low API loading raises blend-control requirements.
• Product-specific coating appearance may require reference benchmarking.
• Small commercial volumes can limit purchasing leverage.

The strongest supplier proposition is therefore operational reliability combined with formulation support, not exclusivity over a standard ingredient.

What revenue exposure does MULPLETA create for excipient suppliers?

Revenue potential depends on generic penetration, treatment volume and tablet weight. The per-tablet excipient value is likely modest because the formulation uses common materials. The larger commercial value lies in the full account:

• Development-grade excipients.
• Engineering and pilot batches.
• Validation-scale material.
• Commercial supply.
• Secondary-source qualification.
• Regulatory documentation.
• Technical troubleshooting.

A supplier can increase account value by securing multiple excipient positions in the formulation rather than selling only one commodity ingredient. Co-processed diluents, superdisintegrants and film-coating systems offer the most defensible commercial positions.

Key Takeaways

• MULPLETA is a 3 mg immediate-release lusutrombopag tablet for periprocedural thrombocytopenia in adults with chronic liver disease.
• Its excipients are conventional: mannitol, microcrystalline cellulose, croscarmellose sodium, magnesium stearate and standard film-coating materials.
• The principal formulation risk is low-dose content uniformity, followed by dissolution sensitivity to lubrication, compression and disintegration.
• The best excipient opportunities are co-processed diluents, premium disintegrants, lubricant-control systems, ready-to-use coatings and dual-source supply programs.
• Biosimilar risk does not apply. Generic and branded competition are the relevant commercial threats.
• A reference-matched formulation is the lowest-risk development path. A differentiated formulation is justified only if it improves manufacturing economics, supply resilience or regional regulatory compliance.
• Patent and Orange Book analysis must be conducted separately from excipient assessment because label composition does not define the complete intellectual-property estate.

FAQs About MULPLETA Excipient Commercial Strategy

Can a generic MULPLETA tablet use different excipients?

Yes. A generic may use different inactive ingredients if the product remains pharmaceutically equivalent, meets quality requirements and demonstrates acceptable performance and bioequivalence.

Which MULPLETA excipient has the greatest commercial opportunity?

Co-processed mannitol-cellulose systems have the strongest opportunity because they can address flow, compactability and low-dose blend uniformity in one platform.

Is MULPLETA a biologic requiring biosimilar development?

No. MULPLETA contains the small-molecule drug lusutrombopag. Competition would proceed through generic-drug pathways rather than biosimilar pathways.

Could titanium dioxide replacement create a reformulation opportunity?

Yes. A titanium-dioxide-free coating could support markets with tighter restrictions on titanium dioxide, provided the replacement delivers equivalent color, opacity, adhesion and stability.

What is the biggest manufacturing risk for a lusutrombopag generic?

The largest risk is achieving consistent content uniformity and dissolution from a low-dose immediate-release tablet while controlling segregation, lubrication and compression variables.

References

1. U.S. Food and Drug Administration. (2023). Mulpleta (lusutrombopag) tablets, prescribing information. Shionogi Inc.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2018). FDA approves Mulpleta for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
4. U.S. Food and Drug Administration. (2017). Inactive ingredient database.
5. U.S. Food and Drug Administration. (2018). Doptelet (avatrombopag) tablets, prescribing information. AkaRx, Inc.